Beckerle Mary C sold $527K of EXEL

Beckerle Mary C sold 9,812 shares of EXELIXIS, INC. (EXEL) at $53.66 ($0.53M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Beckerle Mary C
Published Aug 12, 2026, 11:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
high confidence
Mentioned
$EXEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The newest fact is the specific sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; it does not include any new guidance, trial result, deal, or regulatory action.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and lack of fundamental updates make it unlikely to drive a meaningful repricing by itself.

03

What to watch

The filing does not indicate whether the director’s broader selling program is complete, nor does it provide context on total holdings changes beyond the post-transaction share count.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12 after the 2026-08-10 sale

Background

The article is an SEC Form 4 insider transaction disclosure for EXELIXIS, Inc. (EXEL).

Company-level read

Ticker impact

$EXELNeutralHigh confidence
Context

EXELIXIS director Beckerle Mary C sold 9,812 shares at $53.66 on 2026-08-10 under a 10b5-1 plan, totaling about $526.5K.

Expected impact

Low likelihood of a sustained price move driven by this filing alone.

Evidence & confidence

The disclosure is an open-market sale by a director, explicitly tied to a Rule 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None.

None.

Counterpoint

Insider sales can still reflect private risk perceptions, even when executed under 10b5-1, especially if multiple sales cluster over time.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Beckerle Mary C

    Director who sold 9,812 shares at $53.66 under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.